Intra-Cellular Therapies Inc. (ITCI): Price and Financial Metrics

Intra-Cellular Therapies Inc. (ITCI): $71.49

1.97 (+2.83%)

POWR Rating

Component Grades








Add ITCI to Watchlist
Sign Up

Industry: Biotech




#43 of 360

in industry

ITCI Price/Volume Stats

Current price $71.49 52-week high $76.11
Prev. close $69.52 52-week low $42.01
Day low $69.76 Volume 728,400
Day high $72.31 Avg. volume 848,760
50-day MA $69.62 Dividend yield N/A
200-day MA $61.19 Market Cap 6.92B

ITCI Stock Price Chart Interactive Chart >


  • Sentiment is the dimension where ITCI ranks best; there it ranks ahead of 65.42% of US stocks.
  • ITCI's strongest trending metric is Stability; it's been moving down over the last 26 weeks.
  • ITCI's current lowest rank is in the Stability metric (where it is better than 14.19% of US stocks).

ITCI Stock Summary

  • The ratio of debt to operating expenses for INTRA-CELLULAR THERAPIES INC is higher than it is for about just 7.52% of US stocks.
  • ITCI's price/sales ratio is 15.91; that's higher than the P/S ratio of 93% of US stocks.
  • As for revenue growth, note that ITCI's revenue has grown 123.34% over the past 12 months; that beats the revenue growth of 96.18% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to INTRA-CELLULAR THERAPIES INC are PRCT, RXST, IDN, AIRG, and AQST.
  • Visit ITCI's SEC page to see the company's official filings. To visit the company's web site, go to

ITCI Valuation Summary

  • In comparison to the median Healthcare stock, ITCI's price/earnings ratio is 252.32% lower, now standing at -44.4.
  • Over the past 121 months, ITCI's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ITCI.

Stock Date P/S P/B P/E EV/EBIT
ITCI 2023-12-29 16.4 11.5 -44.4 -43.9
ITCI 2023-12-28 16.5 11.5 -44.7 -44.2
ITCI 2023-12-27 16.9 11.8 -45.7 -45.2
ITCI 2023-12-26 16.3 11.4 -44.2 -43.7
ITCI 2023-12-22 16.1 11.3 -43.6 -43.2
ITCI 2023-12-21 15.3 10.7 -41.4 -40.9

ITCI Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at -63.15%.
  • Its 4 year price growth rate is now at 73.95%.
  • Its year over year revenue growth rate is now at 173.67%.
ITCI's revenue has moved up $187,689,937 over the prior 67 months.

The table below shows ITCI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 188.1159 -304.1775 -297.9639
2022-06-30 138.4531 -330.0933 -321.3639
2022-03-31 102.9207 -294.6255 -303.5047
2021-12-31 83.80302 -259.5435 -284.1257
2021-09-30 70.58636 -254.6017 -259.0909
2021-06-30 55.74775 -238.914 -237.3665

ITCI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ITCI has a Quality Grade of D, ranking ahead of 18.25% of graded US stocks.
  • ITCI's asset turnover comes in at 0.08 -- ranking 278th of 682 Pharmaceutical Products stocks.
  • BHVN, OCX, and BTX are the stocks whose asset turnover ratios are most correlated with ITCI.

The table below shows ITCI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.080 0.907 -0.448
2021-03-31 0.058 0.913 -0.480
2020-12-31 0.038 0.917 -0.536
2020-09-30 0.021 0.928 -0.703
2020-06-30 0.008 0.935 -0.843
2020-03-31 0.003 0.939 -0.803

ITCI Price Target

For more insight on analysts targets of ITCI, see our ITCI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $50.44 Average Broker Recommendation 1.27 (Strong Buy)

Intra-Cellular Therapies Inc. (ITCI) Company Bio

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company was founded in 2002 and is based in New York, New York.

ITCI Latest News Stream

Event/Time News Detail
Loading, please wait...

ITCI Latest Social Stream

Loading social stream, please wait...

View Full ITCI Social Stream

Latest ITCI News From Around the Web

Below are the latest news stories about INTRA-CELLULAR THERAPIES INC that investors may wish to consider to help them evaluate ITCI as an investment opportunity.

11 Most Promising Psychedelic Stocks According to Hedge Funds

In this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can take a look at the 5 Most Promising Psychedelic Stocks. The ability to use chemicals to alter one’s […]

Yahoo | December 20, 2023

Intra-Cellular Therapies (ITCI) is a Great Momentum Stock: Should You Buy?

Does Intra-Cellular Therapies (ITCI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Yahoo | December 19, 2023

3 Biotech Stocks Most Wall Street Analysts Are Bullish About

Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.

Yahoo | December 18, 2023

Intra-Cellular Therapies Inc's EVP, Chief Medical Officer Suresh Durgam Sells 21,262 Shares

In a notable insider transaction, EVP and Chief Medical Officer Suresh Durgam of Intra-Cellular Therapies Inc (NASDAQ:ITCI) sold 21,262 shares of the company's stock on December 13, 2023.

Yahoo | December 16, 2023

IBD 50 Stocks To Watch: Biotech Leader Intra-Cellular Therapies Is Breaking Out Past A New Buy Point

Biotech leader Intra-Cellular Therapies is breaking out past a new buy point, making it one of the best stocks to buy and watch.

Yahoo | December 13, 2023

Read More 'ITCI' Stories Here

ITCI Price Returns

1-mo 6.30%
3-mo 16.32%
6-mo 25.42%
1-year 55.85%
3-year 114.88%
5-year 430.34%
YTD -0.18%
2023 35.34%
2022 1.11%
2021 64.59%
2020 -7.32%
2019 201.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!